Company news

Oric Pharmaceuticals, Inc. news in 2026

Oric Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

November 3, 2026

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

October 23, 2026

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

October 23, 2026

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

October 19, 2026

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

October 5, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

August 3, 2026

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

July 20, 2026

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

July 14, 2026

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

May 4, 2026

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

April 17, 2026

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

March 30, 2026

ORIC Pharmaceuticals to Report Combination Dose Optimization Data from Phase 1b Trial of Rinzimetostat in Patients with mCRPC

March 30, 2026

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

March 26, 2026

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

March 16, 2026

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

February 23, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 6, 2026

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

February 5, 2026

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

January 12, 2026

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026